Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin

References

• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–285, e210–e218.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–271.
   PubMed Web of Science ®Google Scholar
• Li W, Han J, Hu FB, et al. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol. 2012;132:291–298.
   PubMed Web of Science ®Google Scholar
• Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148:995–1000.
   PubMed Web of Science ®Google Scholar
• Xu XC, Feng AP. Characteristics of patients with psoriasis and type 2 diabetes in a central China case-control study. Eur J Dermatol. 2012;22:396–397.
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–285.
   PubMed Web of Science ®Google Scholar
• Hare KJ, Knop FK. Incretin-based therapy and type 2 diabetes. Vitam Horm. 2010;84:389–413.
   PubMed Web of Science ®Google Scholar
• Wang XC, Gusdon AM, Liu H, et al. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol. 2014;20:14821–14830.
   PubMed Web of Science ®Google Scholar
• Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171:155–161.
   PubMed Web of Science ®Google Scholar
• Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1(GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54:2745–2754.
   PubMed Web of Science ®Google Scholar
• Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27:1440–1443.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Knop FK, Thyssen JP, et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014;51:147–150.
   PubMed Web of Science ®Google Scholar
• Chen P, Xu X, Lin L, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019;150:167–173.
   PubMed Web of Science ®Google Scholar
• Schadler ED, Bernhard O, Mehlis SL. Biologics for the primary care physician: review and treatment of psoriasis. Dis Month. 2019;65:51–90.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus a systematic review and meta-analysis. Jama Dermatol. 2013;149:84.
   PubMed Web of Science ®Google Scholar
• Herbert D, Franz S, Popkova Y, et al. High-fat diet exacerbates early psoriatic skin inflammation independent of obesity: saturated fatty acids as key players. J Invest Dermatol. 2018;138:1999–2009.
   PubMed Web of Science ®Google Scholar
• Shimoura N, Nagai H, Fujiwara S, et al. Exacerbation and prolongation of psoriasiform inflammation in diabetic obese mice: a synergistic role of CXCL5 and endoplasmic reticulum stress. J Invest Dermatol. 2018;138:854–863.
   PubMed Web of Science ®Google Scholar
• Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145:379–382.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 2017;26:1112–1117.
   PubMed Web of Science ®Google Scholar
• Almutairi N, Shabaan D. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. Cutis. 2016;97:235.
   PubMed Web of Science ®Google Scholar
• Kong X, Yan D, Sun J, et al. Glucagon-like peptide 1 stimulates insulin secretion via inhibiting RhoA/ROCK signaling and disassembling glucotoxicity-induced stress fibers. Endocrinology. 2014;155:4676–4685.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Pedersen J, Gyldenl Ve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22:150–152.
   PubMed Web of Science ®Google Scholar
• Dai Y, Mehta JL, Hen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2013;27:371–380.
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JSA, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182:5836–5845.
   PubMed Web of Science ®Google Scholar
• Swindell WR, Andrew J, Steve C, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One. 2011;6:e18266.
   PubMed Web of Science ®Google Scholar
• El Malki K, Karbach SH, Huppert J, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor A signaling. J Invest Dermatol. 2013;133:441–451.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 Axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–1350.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873.
   PubMed Web of Science ®Google Scholar
• Marie-Astrid B, Alessandra N, Gabriele GA, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19:530.
   Web of Science ®Google Scholar
• Dozier KC, Cureton EL, Kwan RO, et al. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides. 2009;30:1735–1741.
   PubMed Web of Science ®Google Scholar
• Jing Y, Zongming W, Xilin Z. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol. 2019;107:124–128.
   PubMed Web of Science ®Google Scholar
• Hamminga EA, Lely AJVD, Neumann HAM, et al. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67:768–773.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571.
   PubMed Web of Science ®Google Scholar
• de Menezes Ettinger JE, Azaro E, de Souza CA, et al. Remission of psoriasis after open gastric bypass. Obes Surg. 2006;16:94–97.
   PubMed Web of Science ®Google Scholar